Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain — DARIOS  

Atherosclerosis Risk Clinical Trial

Official title: Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population

Status Completed

Clinical Trial Summary

The present project is aimed at determining the prevalence of LDL-C <130 mg/dl with hsCRP ≥2mg/l, and of HDL-C < 40 mg/dl in Spain together with the estimation of cardiovascular risk, to analyze the contribution of measuring hsCRP for primary prevention purposes. In a subgroup of that population a number of inflammatory and oxidative status biomarkers would be also measured to better understand the meaning of elevated hsCRP.The study aim to analyze data already collected in studies (11 studies will participate) carried out in Spain, in 10 Spanish regions, after the year 2000.

Clinical Trial Description

n/a

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerosis Risk
• Dyslipaemia
• Increased hsCRP
• Inflammatory and Oxidative Status in the Spanish Population

• NCT number: NCT00998062
• Study type: Observational
• Source: AstraZeneca
• Status: Completed
• Phase: N/A
• Start date: November 2009
• Completion date: October 2011